Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: RJMC who wrote (3813)	1/29/2001 1:27:51 AM
From: Gary Mohilner	Read Replies (1) \| Respond to of 5665

Bob, I agree with your assessment. One critical thing will be GSK's approach to efficacy news. If they want their shareholders to properly know what they have, we'll get a clear statement, otherwise it will be wordsmithed to keep investors guessing. I believe the efficacy milestone is for 50% tumor reduction, if that's clearly stated, we'll be off to the races. The next few weeks could bring on a lot of news. IND acceptance, quarterly report, presentations at conferences, possibly another partnership, completion of the Single Dose Trial at any time, and the Efficacy Milestone. IMGN is doing the right thing, they're completely on track wrt their business plan, and I believe the drug is working as well as they could have possibly hoped. As you said, with proof of efficacy the value of each partnership, news announcement, etc. will grow tremendously. It's just a matter of time, the efficacy milestone will either tell the tale, or it will be told by the Doctors at the appropriate conference. Gary